Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1676
This examiner grants 43% of resolved cases
Joseph Fischer is a patent examiner in Tech Center 1600 and Art Unit 1654. He has reached a resolution in 343 cases. The data shows an allowance rate of 43.4 percent for these applications. This percentage indicates that fewer than half of the cases assigned to him result in a patent grant. Practitioners can use this 43.4 percent rate to understand the more rigorous examination environment presented by this examiner.
The impact of interviews on prosecution outcomes is very high for this examiner. The data reveals an interview lift of 45.6 percent. This metric suggests that conducting an interview is associated with a dramatic increase in the probability of allowance. An interview lift of 45.6 percent indicates that direct communication is perhaps the most effective way to resolve issues and move an application toward a grant. Practitioners should prioritize scheduling an interview early in the process.
The median days to allowance for successful cases is 1225. This duration represents the middle value of the time taken from filing to the issuance of a patent. A median of 1225 days provides a specific timeline for applicants to consider when managing their expectations. These metrics are based on 343 resolved cases, offering a data-grounded perspective on the examiner's historical prosecution patterns.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17759757 | NANOMATERIALS FOR TARGETED TREATMENT AND IMAGING OF ANEURYSMAL MICROENVIRONMENT | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17176750 | FASTING MIMICKING AND ENHANCING DIET FOR TREATING HYPERTENSION AND LIPID DISORDERS | Final Rejection | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 18370695 | MULTIVALENT PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | Non-Final OA | NEW YORK UNIVERSITY |
| 18106009 | CASPOFUNGIN DERIVATIVES AND ASSAYS FOR EVALUATING ANTIFUNGAL TREATMENT EFFICACY | Non-Final OA | RAMOT AT TEL AVIV UNIVERSITY LTD. |
| 17312703 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | Final Rejection | FRED HUTCHINSON CANCER CENTER |
| 18027695 | Wnt SIGNALING PATHWAY INHIBITOR | Non-Final OA | OSAKA UNIVERSITY |
| 18249934 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Non-Final OA | The University of Western Australia |
| 18554511 | TREATMENT OF NEUROPATHIC CORNEAL PAIN WITH NGF | Non-Final OA | TUFTS MEDICAL CENTER, INC. |
| 18283164 | GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE | Final Rejection | BrightGene Bio-Medical Technology Co., Ltd. |
| 18023202 | MEDICINE CONTAINING METHEMOGLOBIN ENDOPLASMIC RETICULUM AS ACTIVE INGREDIENT AND USE THEREOF | Final Rejection | KIMIGAFUCHI GAKUEN |
| 17209615 | COMBINATION THERAPY OF HBV AND HDV INFECTION | Non-Final OA | MYR GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy